Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela M Carter

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Blood|April 21, 2011
Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarctionShirley Uitte de Willige, Megan Miedzak, Angela M Carter, et al.
Atherosclerosis|August 25, 2009
Symmetric dimethylarginine predicts all-cause mortality following ischemic strokeFriedrich Schulze, Angela M Carter, Edzard Schwedhelm, et al.
Human Mutation|September 8, 2011
A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedemaAmy L Cilia La Corte, Angela M Carter, Gillian I Rice, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 20, 2009
Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT studyFrances M K Williams, Angela M Carter, Bernet Kato, et al.
Ejhaem|July 18, 2022
Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent β-thalassaemia in the United Kingdom: A mixed methods observational studyFarrukh Shah, Paul Telfer, Mark Velangi, et al.
British Journal of Haematology|August 16, 2002
Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-aged menHans P Kohler, Robert A S Ariëns, Andrew J Catto, et al.
Oncotarget|February 1, 2019
Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancerKarine Pozo, Stefan Zahler, Keisuke Ishimatsu, et al.
European Journal of Haematology|April 11, 2022
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the NetherlandsSimone Claudiani, Jeroen J W M Janssen, Jenny Byrne, et al.
Diabetes & Vascular Disease Research|January 19, 2012
Complement C3 is a novel plasma clot component with anti-fibrinolytic propertiesJoanna-Marie Howes, Victoria R Richardson, Kerrie A Smith, et al.
Theranostics|February 22, 2018
Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug deliveryJonathan O Martinez, Roberto Molinaro, Kelly A Hartman, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Blood|April 21, 2011
Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarctionShirley Uitte de Willige, Megan Miedzak, Angela M Carter, et al.
Atherosclerosis|August 25, 2009
Symmetric dimethylarginine predicts all-cause mortality following ischemic strokeFriedrich Schulze, Angela M Carter, Edzard Schwedhelm, et al.
Human Mutation|September 8, 2011
A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedemaAmy L Cilia La Corte, Angela M Carter, Gillian I Rice, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 20, 2009
Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT studyFrances M K Williams, Angela M Carter, Bernet Kato, et al.
Ejhaem|July 18, 2022
Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent β-thalassaemia in the United Kingdom: A mixed methods observational studyFarrukh Shah, Paul Telfer, Mark Velangi, et al.
British Journal of Haematology|August 16, 2002
Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-aged menHans P Kohler, Robert A S Ariëns, Andrew J Catto, et al.
Oncotarget|February 1, 2019
Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancerKarine Pozo, Stefan Zahler, Keisuke Ishimatsu, et al.
European Journal of Haematology|April 11, 2022
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the NetherlandsSimone Claudiani, Jeroen J W M Janssen, Jenny Byrne, et al.
Diabetes & Vascular Disease Research|January 19, 2012
Complement C3 is a novel plasma clot component with anti-fibrinolytic propertiesJoanna-Marie Howes, Victoria R Richardson, Kerrie A Smith, et al.
Theranostics|February 22, 2018
Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug deliveryJonathan O Martinez, Roberto Molinaro, Kelly A Hartman, et al.
Pageof 7